The BU-CTSI is a center of expertise providing tools, services and resources to clinical investigators, maximizing the impact of discoveries & speeding the translation of research into improved patient care


193 matching studies

Study is registered in ResearchMatch
Sponsor Condition of Interest
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refr1
Novartis Pharmaceuticals Lupus Erythematosus, Systemic Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN). expand

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).

Type: Interventional

Start Date: Sep 2024

open study